Galectin Therapeutics, Inc. (GALT)

Nasdaq Stock Exchange
USD
US3632252025
9 September 2002  –  27 September 2022

Performance

Annualized Return
-9.61%
Sharpe Ratio
0.4
Maximum Drawdown
-99.02%

Metrics

Metric Galectin Therapeutics, Inc.
Initial Balance $10,000
Final Balance $1,317
Returns   [View more details]
Month-To-Date -16.84%
Year-To-Date -23.67%
3M 25.4%
6M -9.2%
Annual Return (3Y) -24.25%
Annual Return (5Y) -6.66%
Annual Return (All) -9.61%
Risk   [View more details]
Annual Volatility 103.96%
Max Drawdown -99.02%
Sharpe Ratio 0.4
Sortino Ratio 0.68
Adjusted Sortino (S/√2) 0.48

  • Initial balance: The amount of starting capital used to invest in the asset or portfolio. In this case, we're starting with a $10,000 investment on September 2002.
  • Final balance: The amount of capital we've accrued over time as of September 2022.
  • Annual return: Also known as annualized return, or CAGR (Compound Annual Growth Rate), measures how much an investment has increased on average each year, during a specific time period. The time period in this case is approximately 20 year(s). Even a small difference in return can have a big impact on the final balance over a long period of time.
  • Annual volatility: Basically indicates how much, in percentage points, the investment can deviate from its annual return, under most circumstances. An investment with an annual return of 5% and an annual volatility of 10% would indicate returns from approximately -5% to 15% most of the time. A lower volatility is usually preferred to ensure more steady returns over time.
  • Best year: The best performance attained over its lifetime in a given year.
  • Worst year: The worst performance undergone over its lifetime in a given year.
  • Max drawdown: The largest percentage drop from a peak to a trough of an asset or portfolio, before a new peak is attained. Maximum drawdown is an indicator of downside risk over a specified time period.
  • Sharpe Ratio: The Sharpe ratio measures the performance of an investment compared to a risk-free asset, after adjusting for its risk. A Sharpe Ratio above 1 is considered good.
  • Sortino Ratio: The Sortino Ratio is a variation of the Sharpe ratio that only penalizes the investment for negative volatility/outcomes, and not for positive volatility. A Sortino Ratio above 1 is considered good.
  • Adjusted Sortino Ratio: Sortino Ratio/√2. To allow for comparing the Sortino ratio to the Sharpe ratio, we multiply the risk measure of the Sortino ratio by the square root of 2 (which is the same as dividing the Sortino ratio by the square root of 2).
  • Ulcer Index: The Ulcer Index (UI) is a technical indicator that measures downside risk in terms of both the depth and duration of price declines.
  • Gain to Pain Ratio: The sum of all returns divided by the absolute value of the sum of all negative returns. In essence, the GPR shows the ratio of net returns to the losses incurred in getting those returns.

Annualized Returns

Annual Return 1y Annual Return 3y Annual Return 5y Annual Return 10y Annual Return 20y Annual Return
Galectin Therapeutics, Inc. -61.93% -24.25% -6.66% -3.39% -11.93% -9.61%

Annual Returns

Year Galectin Therapeutics, Inc.
2002 45.5%
2003 35.74%
2004 -36.71%
2005 22%
2006 -85.25%
2007 55.56%
2008 -87.14%
2009 211.11%
2010 221.43%
2011 6.67%
2012 -64.41%
2013 294.15%
2014 -57.05%
2015 -52.74%
2016 -40.26%
2017 240.89%
2018 2.69%
2019 -16.62%
2020 -21.68%
2021 -7.59%
2022 -23.67%

Galectin Therapeutics, Inc. had 10 positive years and 11 negative years. That's a positive ratio of 48%.

Monthly Returns

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec YTD
2002 0% 0% 0% 0% 0% 0% 0% 0% 70.5% -12% 0% -3% 56.4%
2003 -5.5% 7.3% 3.7% -15.4% 0% 71.8% -6.7% -1.2% 34.1% -32.4% -0.5% 6.8% 53.7%
2004 3.5% 10% -5.1% -10.5% -13.6% 23.9% -6.1% -21.4% -28.8% 0.9% -22.1% 47.9% -16.8%
2005 15.6% -3.1% -1.8% 9.1% -10% 6.7% 2.1% -3.1% 0.4% -7.3% 8.3% 6.3% 34.7%
2006 -1.6% 11.7% 10.4% -8.4% -5.3% -1.9% -36.2% -56.2% -6.8% -23.2% 4.8% -31.8% -136.7%
2007 -35.6% 313.8% -38.3% 14.9% 0% -58.8% 20% -16.7% 91.4% 20.9% -19.8% 7.7% 156%
2008 -17.1% -29.3% 4.9% -9.3% -2.6% -10.5% 5.9% -5.6% -41.2% -30% -28.6% -10% -83.3%
2009 33.3% 50% 22.2% 113.6% -0% -36.2% 46.7% -4.5% -21.4% 3% -14.7% -3.4% 218.3%
2010 0% 50% 4.8% 59.1% 5.7% -3.6% 8% -31.2% 49.1% -13.9% 1.5% 30.4% 161.9%
2011 37.8% -4.8% -11.9% 29.8% 0% -9.6% -15.6% -15.5% -1.1% 3.5% -10.1% 20% 33%
2012 -15.6% 6.2% -21.7% -23% -24.8% -12.4% 14.1% -7.7% 3.2% -14.8% 5.3% 2.5% -66.5%
2013 25.4% 32.3% 5.6% 30.4% -9.3% 0.1% 40% 24.2% 34.9% 4.8% -21.5% -1.5% 176.4%
2014 69.7% 23% -9.2% -24.6% 12% 6.8% -55.5% 2% -19.6% 7.8% -26.8% -12.6% 1.3%
2015 -7.2% 5.6% -1.5% -10.7% -16.1% 8.8% -5.9% -14% 5.9% 16.7% -26.7% -18% -46%
2016 -14% -9.2% 11.7% -0.7% 4.2% -0.7% 11.6% 4.9% -34.3% -36.3% 13.9% 19.5% 3.8%
2017 1% 91.9% 21.1% 33% -25.8% 8.4% -18.7% -14% 24.4% 14.5% -3.7% 41.5% 183.8%
2018 38% -10.8% 15.3% -29.7% 52.6% 25.2% -20.6% 28.1% -7.1% -28.3% 14.6% -30.6% 54.2%
2019 41.1% 7.6% -1.9% -16.2% -5.8% 3% -10.8% -10% 10.2% 8.4% -18.8% -11.5% 1.3%
2020 -8% -19.4% -7.5% 26.8% 21.9% 1% -14.7% 1.5% 0.8% -4.9% 2.4% -13.8% 11.6%
2021 -12.5% 14.3% -3.1% 103.7% -10.2% -19.4% -14.1% 42.9% -1.3% -18.3% -17% -21.3% 31.5%
2022 -6.8% -3.1% -13.9% -3.7% -16.8% 1.6% 72.5% -15.9% -16.8% 0% 0% 0% -4.1%
Pos 47.4% 65% 45% 45% 36.8% 55% 45% 30% 52.4% 45% 40% 45% 71.4%
Avg 7.4% 27.2% -0.8% 13.4% -2.3% 0.2% 0.8% -5.7% 7% -7% -8% 1.3% 39.3%

Other Return Metrics

Metric Galectin Therapeutics, Inc.
Cumulative Return -86.83%
Enh Ann Return 22.93%
Best Year 294.15%
Worst Year -87.14%
Best Month 313.79%
Worst Month -58.82%
Best Day 78.28%
Worst Day -60.8%
Win Ratio (Yearly) 47.62%
Win Ratio (Quarterly) 48.15%
Win Ratio (Monthly) 46.03%
Win Ratio (Daily) 46.32%

Annual Volatility

Annual Volatility 1y Annual Volatility 3y Annual Volatility 5y Annual Volatility 10y Annual Volatility 20y Annual Volatility
Galectin Therapeutics, Inc. 73.51% 85.07% 89.67% 95.05% 103.04% 103.96%

Sharpe Ratio

Sharpe Ratio 1y Sharpe Ratio 3y Sharpe Ratio 5y Sharpe Ratio 10y Sharpe Ratio 20y Sharpe Ratio
Galectin Therapeutics, Inc. -0.95 0.08 0.36 0.43 0.37 0.4

3-Year Rolling Sharpe Ratio

The rolling Sharpe Ratio gives a clue about the continued consistency or stability of the risk-adjusted returns.

Drawdown Periods

Simply said, a drawdown is the "pain" period experienced by an investor between a peak (new highs) and subsequent valley (a low point before moving higher). In the table below are the fifth largest drawdowns encountered for the portfolio/asset in question.

Galectin Therapeutics, Inc.

start valley end Drawdown days
2003-09-12 2008-11-17 - -99.02% 6955
2002-09-13 2003-05-29 2003-06-13 -34.29% 273
2003-07-03 2003-08-06 2003-09-09 -15.96% 68
2003-06-16 2003-06-16 2003-06-17 -5% 1
2003-06-20 2003-06-20 2003-06-23 -3.46% 3

The Galectin Therapeutics, Inc. took approximately 49 months on average to recover from a major drawdown. The longest drawdown lasted 232 months.

Underwater plot

The underwater plot shows you the drawdown periods on a chart. Whereas the performance chart usually gives you a positive viewpoint, the underwater plot gives you a pessimistic viewpoint. It helps you to visualize downtrends that occurred and how long it took for the portfolio's value to rebound to hit a new high after suffering a loss.

Other Risk Metrics

Metric Galectin Therapeutics, Inc.
Sharpe Ratio 0.4
Sortino Ratio 0.68
Adjusted Sortino (S/√2) 0.48
Calmar Ratio -0.1
Omega Ratio -0.1
Gain to Pain Ratio 0.09
Winckel Ratio 52.38
Ulcer Index 0.83
Kelly Criterion 3.7%
Skew 2.12
Kurtosis 21.67
End of: